Clinical data | |
---|---|
Trade names | Elelyso, Uplyso (Latin America) |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 18.9-28.7 minutes |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C2580H3918N680O727S17 |
Molar mass | 56638.78 g·mol−1 |
Taliglucerase alfa, sold under the brand name Elelyso among others, is a biopharmaceutical medication developed by Protalix and Pfizer.[2][3][full citation needed] The drug, a recombinant glucocerebrosidase used to treat Gaucher's disease, is the first plant-made pharmaceutical to win approval by the U.S. Food and Drug Administration (FDA).[4][5] Each vial has 200 units of taliglucerase alfa.